Analyst Ratings February 17, 2026

Compass Point Raises Upstart to Neutral, Cites 2028 Targets as Valuation Reference Point

Firm increases price target to $30 as management's multi-year growth and margin goals provide a basis for applying a conventional multiple

By Leila Farooq UPST
Compass Point Raises Upstart to Neutral, Cites 2028 Targets as Valuation Reference Point
UPST

Compass Point upgraded Upstart Holdings Inc (UPST) from Sell to Neutral and lifted its price target to $30 from $20, aligning the target with the stock's recent trading level. The adjustment follows Upstart's fourth-quarter 2025 results and the company’s 2025-2028 guidance, which includes a roughly 35% revenue compound annual growth rate and a terminal adjusted EBITDA margin of about 25% by 2028. Other analysts have offered divergent views, leaving the consensus mixed.

Key Points

  • Compass Point upgraded Upstart from Sell to Neutral and raised its price target to $30, based on 2x the firm’s 2028 estimated tangible book value of $15.21.
  • Upstart provided 2025-2028 guidance: roughly 35% revenue CAGR and a terminal adjusted EBITDA margin target near 25%, and recent trailing twelve-month revenue rose 58.87% to $1.08 billion with EBITDA of $99.13 million.
  • Analyst views are mixed - Goldman Sachs also raised its rating to Neutral with a $35 target, while Citizens downgraded to Market Underperform with a $20 target; the market debate centers on valuation versus multi-year execution.

Compass Point moved Upstart Holdings Inc (NASDAQ: UPST) off a Sell rating and to Neutral on Tuesday, while raising its price target to $30 from $20. That new target sits close to Upstart’s then-trading price of $30.68. According to InvestingPro data, the company's share price is trading near a 52-week low of $29.61 after a 62.78% decline over the past year.

The upgrade is notable because it marks the first time Compass Point has shifted away from a Sell recommendation since it began covering Upstart in March 2023. The firm said its $30 price objective is grounded in a valuation equal to two times the company’s estimated tangible book value for the year 2028, which Compass Point places at $15.21. InvestingPro’s Fair Value assessment is consistent with the view that Upstart may be undervalued at current market levels.

Compass Point said the change in rating follows Upstart’s fourth-quarter 2025 financial disclosure and the company’s own multi-year guidance. Management provided a 2025-2028 revenue compound annual growth rate outlook of about 35% and set a terminal adjusted EBITDA margin target of roughly 25% by the terminal year. Those targets, together with recent results, form the basis for Compass Point’s expectation that investors will have a clearer reference point for valuing the stock around fiscal year 2028.

Upstart reported strong recent growth on several measures. Revenue for the trailing twelve months rose 58.87% to $1.08 billion, and EBITDA reached $99.13 million. In the company’s fourth-quarter 2025 results, revenue beat the consensus estimate while earnings per share missed expectations: the company posted EPS of $0.17 versus the forecasted $0.46, a negative surprise of 63.04%. Revenue for the quarter came in at $296.0 million versus an anticipated $288.45 million, a positive surprise of 2.64%.

Compass Point indicated that the presence of clear multi-year targets should allow the market to transition from historical trading patterns to valuation debates centered on the company’s ability to deliver on its fiscal year 2028 outlook. The analyst firm suggested investors may be able to apply a reasonable multiple to Upstart shares if management executes on the guidance.

Analyst reaction beyond Compass Point remains mixed. Goldman Sachs also upgraded Upstart from Sell to Neutral and set a higher price target of $35.00, reflecting a more balanced assessment of upside and downside. By contrast, Citizens moved in the opposite direction, downgrading the stock from Market Perform to Market Underperform and lowering its price target to $20.00. Citizens cited valuation concerns and referenced the company’s three-year medium-term guidance as part of its rationale.

These differing analyst conclusions underscore a split view among sell-side firms about how to weigh Upstart’s top-line momentum, margin targets and current market valuation. With the company trading near recent lows yet presenting aggressive growth and margin aspirations for 2028, the debate over an appropriate valuation multiple appears likely to continue until there is clearer evidence of execution against the multi-year plan.

Risks

  • Execution risk on management’s 2025-2028 targets - the company’s ability to hit the roughly 35% revenue CAGR and 25% terminal adjusted EBITDA margin underpins valuation assumptions.
  • Valuation uncertainty - differing analyst price targets and recent trading near a 52-week low indicate continued debate over appropriate multiples and fair value.
  • Earnings volatility - the recent quarter showed a revenue beat but a substantial EPS miss, highlighting potential near-term profitability swings that affect investor confidence and market pricing.

More from Analyst Ratings

DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026